International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease

While P-RMS is known to be an aggressive histologic sarcoma subtype, one-third of patients with primary localized disease may be cured. The contribution of chemotherapy and radiotherapy to the cure rate remains unclear. Post-metastatic outcomes mirror those observed in other sarcomas.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-01-20
DOI
https://doi.org/10.1016/j.esmoop.2025.106044
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease

DD Wong, AJ Lazar, RA Denu, Elena Di Blasi et al.
ESMO Open
Sarcoma Diagnosis and Treatment
article

International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease

DD Wong, AJ Lazar, RA Denu, Elena Di Blasi, I.-M. Schaefer, M. Sbaraglia, Silva Ljevar, Vladimir Andelkovic, T. Wei-Wu Chen, Roberto Scanferla, GLORIA MARQUINA, Benedetta Chiusole, Jade Davis, Stefano Taverna, Claudia Giani, J.V.M.G. Bovée, V. A. Bhadri, A.P. dei Tos, Elena Bellan, Fernando Augusto Batista Campos, HS Kim, Prof Khin Thway, Antonella Brunello, R. Miceli, I. Han, A.S. Garcia, C. Antonescu, K. Ogura, A. Mazzocca, A. Napolitano, S. Stacchiotti, M.S. Nakazawa, M.H. Abreu, S. Bae, G.G. Baldi, V. Yang, A. Gronchi
article en

Abstract

While P-RMS is known to be an aggressive histologic sarcoma subtype, one-third of patients with primary localized disease may be cured. The contribution of chemotherapy and radiotherapy to the cure rate remains unclear. Post-metastatic outcomes mirror those observed in other sarcomas.

ESMO OpenVol. 11(2)
Brigham and Women's Hospital (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), University of Padua (IT), Institute of Cancer Research (GB), Leiden University Medical Center (NL), Peter MacCallum Cancer Centre (AU), Hospital de Sant Pau (ES), Princess Alexandra Hospital (AU), Sir Charles Gairdner Hospital (AU), Seoul National University Hospital (KR), Hospital Clínico San Carlos (ES), AC Camargo Hospital (BR), Institute of Cancer Research (CA), Chris O’Brien Lifehouse (AU), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES), Instituto Português de Oncologia Francisco Gentil (PT), Istituto Oncologico Veneto (IT), Azienda Ospedaliero-Universitaria Careggi (IT), Royal Marsden Hospital (GB), National Taiwan University Hospital (TW), National Cancer Centre Singapore (SG), Campus Bio Medico University Hospital (IT), Azienda Ospedale - Università Padova (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Hospital of Prato (IT), Indiana University School of Medicine, Indiana University – Purdue University Indianapolis (US)
Good health and well-being
Openalex Percentile: Top 82%
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.